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Abstract
Next Generation Sequencing (NGS) has the potential of becoming an important tool in clinical diagnosis and therapeutic
decision-making in oncology owing to its enhanced sensitivity in DNA mutation detection, fast-turnaround of samples in
comparison to current gold standard methods and the potential to sequence a large number of cancer-driving genes at the
one time. We aim to test the diagnostic accuracy of current NGS technology in the analysis of mutations that represent
current standard-of-care, and its reliability to generate concomitant information on other key genes in human oncogenesis.
Thirteen clinical samples (8 lung adenocarcinomas, 3 colon carcinomas and 2 malignant melanomas) already genotyped for
EGFR, KRAS and BRAF mutations by current standard-of-care methods (Sanger Sequencing and q-PCR), were analysed for
detection of mutations in the same three genes using two NGS platforms and an additional 43 genes with one of these
platforms. The results were analysed using closed platform-specific proprietary bioinformatics software as well as open third
party applications. Our results indicate that the existing format of the NGS technology performed well in detecting the
clinically relevant mutations stated above but may not be reliable for a broader unsupervised analysis of the wider genome
in its current design. Our study represents a diagnostically lead validation of the major strengths and weaknesses of this
technology before consideration for diagnostic use.
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Introduction
Molecular cancer diagnostics in clinical practice is constantly
and rapidly evolving. With the need to identify standard-of-care
mutations in companion diagnostics to predict therapeutic
response, cancer treatment has been revolutionised.
Since the 1970s, the Sanger method [1] is the gold standard for
mutation analysis in cancer diagnostics; however its low-through-
put and relative low sensitivity, long turnaround time and overall
cost [2] have called for new paradigms. Next Generation
Sequencing (NGS) can massively parallel sequence millions of
DNA segments and, in principle, offers benefits relating to possible
lower costs, increased workflow speed and enhanced sensitivity in
mutation detection [3]. As whole-genome-sequencing may be
unaffordable for routine diagnostics, the targeted sequencing of
exon coding regions or a subset of ‘genes of interest’ offered by
NGS is an attractive proposition a priori [4]. When compared
with single-gene analysis, the use of NGS in diagnostics would
allow the analysis of more than one therapeutic avenue as well as
the generation of other valuable information for research
purposes. To be a plausible option, a) NGS technologies must
be as efficient as the current detection methods in the diagnosis of
those single genes that currently represent standard-of-care; and b)
the extra information generated must be of sufficient quality to
consider alternative therapies or be accepted for downstream
research endeavours. Such validations should include, at least, the
V600E mutation in the BRAF gene, indicating which malignant
melanoma patients respond effectively to vemurafinib treatment
[5,6], mutations of the EGFR gene to predict which lung
adenocarcinomas respond to tyrosine kinase inhibitor (TKI)
treatment, primarily those identified in amino acid (aa)719 exon
18, exon 19 deletions, aa768 exon 20 and aa858 exon 21 [7,8],
and KRAS mutations in exon 2 (codon 12 and 13) to predict lack of
response to targeted monoclonal antibodies in colorectal cancer
[9]. To test the presumed advantage of NGS versus single-gene
approaches, the bench validation must be accurately executed and
major challenges in bioinformatic analysis met. Indeed, the clinical
utility of NGS has been described in other disease settings. For
example, NGS is as reliable as Sanger sequencing in the detection
of a range of mutations associated with hereditary cardiomyop-
athy. The authors concluded that targeted NGS of a disease-
specific subset of genes is equal to the quality of Sanger sequencing
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and it can therefore be reliably implemented as a stand-alone
diagnostic test [10].
Here, we test the validity of the current technical designs for the
NGS analysis of BRAF, EGFR and KRAS (and of more than 40
other key oncogenes), exploring all the bench and bioinformatics
analytical variables to confirm the possible application of these
technologies for routine cancer diagnostics.
Materials and Methods
(See S1 for choice of clinical materials, DNA extraction
protocols, sequencing analysis by Sanger and q-PCR platforms,
general sequencing workflow for NGS analysis and ethical
framework of the study). Thirteen aliquots of tumour DNA
extracted from formalin-fixed-paraffin-embedded (FFPE) malig-
nant melanoma, lung adenocarcinoma and colon carcinoma, and
genotyped by Sanger/q-PCR sequencing for BRAF, EGFR and
KRAS status, respectively, were obtained from the Northern
Ireland Biobank following ethical approval (NIB12-0049). The
data set has been deposited in NCBI SRA http://www.ncbi.nlm.
nih.gov/sra (SRP023265).
IonTorrent sequencing
PGM sequencing was performed according to IonTorrent
protocols using 10 ng DNA (Table S1), IonAmpliSeqTMCancer
Panel primer pool and IonAmpliSeqTMLibrary Kit 2.0 Beta (Life
Technologies) for whole-exon-sequencing of BRAF, EGFR and
KRAS and targeted ‘‘hot-spot’’ regions in 43 other cancer-related
genes (http://tools.invitrogen.com/content/sfs/brochures/IonAmpliSeq_
CancerPanel_Flyer_CO32201_06042012.pdf). Template preparation
was performed on the Ion OneTouchTM system for 100 bp libraries
(Life Technologies). QCs were performed using the IonSphereTMQu-
ality Control Kit (according to the protocol) ensuring that 10-30% of
template positive Ion spheres were targeted in the emPCR reaction.
Prior to loading onto 314 chips, sequencing primer and polymerase
were added to the final enriched Ion spheres.
454 GS Junior sequencing
GS Junior Titanium Fusion primers for BRAF (exon 15) and
KRAS (exon 2) were designed incorporating 8 Roche multiplex
identifier (MID) barcodes. BRAF and KRAS libraries were
prepared adhering to the Roche Amplicon Library Preparation
manual. For EGFR, libraries were prepared using the EGFR18-
21MastR kit (Multiplicom), according to the accompanying
protocol. Clonal amplification onto DNA capture beads was
performed manually adhering to the emPCR Amplification
manual-Lib A (Roche). After DNA library bead enrichment,
adaptor-specific sequencing primers were annealed and libraries
were sequenced according to the Sequencing Manual on the GS
Junior (Roche).
Bioinformatics analysis
IonTorrent ‘closed’ bioinformatics. was performed using
IonTorrent Version (V) 2.0.1 (ID.1-ID.10 and ID.12) and re-
analysed by V2.2 upgrade (all samples). The HG19 reference was
used for alignment. For 314 chip sequencing a threshold of
$200,000 final quality library reads was applied.
GS Junior ‘closed’ bioinformatics. was performed using
Roche 454 Amplicon Variant Analyzer (AVA) V2.7 for BRAF and
KRAS. HG19 BRAF and KRAS regions were used as the
alignment reference, respectively. Multiplicom provided scripts
for analyzing their EGFR18-21MastR Kit sequencing results. A
threshold of$50,000 final quality library reads was applied for all.
Variants obtaining a frequency of detection $5% were considered
in the analysis.
‘Open’ CLC Genomics Workbench. V5.5 was employed to
comparatively analyse data generated by IonTorrent software
(PGM) and AVA (GS Junior). HG19 was downloaded within
CLC, incorporating tracks from the COSMIC database. Align-
ment was carried out by 2 methods: a loose alignment setting to
identify large base changes, for example deletions, and a stringent
alignment setting for quality based variant detection (QBVD) of
single nucleotide variants (SNVs), both capped at 5% mutation
frequency. Three QBVD thresholds were applied: (i) the lowest
coverage and (ii) the second lowest coverage required to detect
standard-of-care variants. A third arbitrary threshold (iii) at ,2-
fold higher coverage than (ii) was also employed. Coverage
equated to (i) = 71 (aa719 exon 18; EGFR), (ii) = 259 (aa858 exon
21; EGFR) and (iii) = 500, meaning any SNVs with coverage equal
to or above these thresholds were included in CLC analysis and
compared. For IonTorrent, four sets of data were retrieved:
V2.0.1, CLC_V2.0.1 (ID.1-ID.10 and ID.12), V2.2 and
CLC_V2.2 (all samples), and for GS Junior, 2 sets: AVA and
CLC_AVA. Ultimately, a variant ‘passed’ if detected in 2/4 of the
resultant analyses enabling a consensus list of SNVs and standard-
of-care genes across different software tools and versions.
Concordance (rho.c value) analysis was performed evaluating the
frequency of variants detected against the reference between the
following groups: CLC_IonTorrentV2.2 vs IonTorrentV2.2; Ion
TorrentV2.2 vs AVA; AVA vs CLC_AVA.
Results
EGFR analysis
Lung adenocarcinoma (ID.3-ID.10). Deletion in exon 19
affecting aa745_750 was detected in 25% of patients (ID.7 and
ID.10) and was concordant across Sanger, q-PCR (Cobas),
IonTorrent (V2.2) and Roche GS Junior platforms (mean
coverage depth .2500, Table 1). A variant in exon 20 G/A
aa803 was detected in ID.10 by IonTorrent but disregarded as re-
analysis by CLC and subsequent GS Junior sequencing did not
confirm the base call hence not meeting our variant ‘passed’
criteria outlined in Materials and Methods. Lowering the
stringency of the bioinformatic analysis allowed the detection of
standard-of-care TKI-sensitising mutations [7,8] that were not
detected by single gene analysis and thus, are likely to represent
false-positive results. For example, in ID.9, a SNV was detected in
exon 18 G/T aa719 by IonTorrent and, as a result of applying the
lowest threshold, this SNV was also detected by CLC re-analysis at
coverage of 89. By employing more stringent thresholds
(QBVDii = 259; QBVDiii = 500), this standard-of-care mutation
was not detected. Variants that ‘passed’ the 2/4 analysis criteria
but not identified by the gold standard Sanger/q-PCR methods
were in ID.4, ID.5 and ID.9 by IonTorrent (and CLC re-analysis)
at the sensitizing mutation EGFR exon 20 G/T aa768 [8]. This
finding was discordant with GS Junior and Sanger/q-PCR.
Sequencing coverage averaged at 477 (for all 3 QVBD thresholds).
Of note, when applying the highest threshold (QVBDiii = 500)
only, this standard-of-care mutation would only have been called
in ID.4. Variant ‘passed’ in 4/4 NGS analysis was the important
activating mutation in ID.9 at exon 21 T/G aa858 (also identified
by Sanger/q-PCR). Importantly, by applying the highest QBVDiii
threshold of 500, this key SNV would only have been called in 1/4
analysis of ID.9. Variants ‘passed’ in 4/4 NGS analysis were the
two standard-of-care mutations in exon 18 G/T aa719 and exon
20 G/T aa768 in ID.8, concordant with Sanger/q-PCR (Table 1).
Even when applying the most stringent threshold (QBVDiii = 500),
Application of NGS for Clinical Cancer Diagnostics
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both therapeutic mutational targets were called. In addition, two
silent germline polymorphisms [10,11] were detected in 4/4 NGS
analyses: a SNV at exon 21 C/T aa836 in ID.9 and a SNV at
exon 20 G/A aa787 in all lung adenocarcinoma samples.
Frequencies of EGFR SNVs were concordant between IonTorrent
and re-analysis by CLC (rho.c.est = 0.9957) and similarly between
GS Junior’s AVA data and CLC_AVA (rho.c.est = 0.9953),
verifying a strong overlap between platform-specific proprietary
software and open third-party tools. There was a poor concor-
dance between IonTorrent software and GS Junior’s AVA
pipeline for matched EGFR SNV frequencies, rho.c est = 0.7718.
Malignant melanoma (ID.1 and ID.2). The therapeutic
TKI target in EGFR exon 18 aa719 was detected in ID.2 by
IonTorrent and CLC_IonTorrent analysis, albeit at the least
stringent threshold of 71. No other mutations in EGFR were
considered as they have previously been described as silent
germline polymorphisms [10,11] or did not meet the variant
‘passed’ criteria (exon 20 aa804) (Table 1).
Colorectal carcinoma (ID.11-ID.13). In 1/3 clinical sam-
ples, IonTorrent and CLC_IonTorrent analysis identified a SNV
at exon 18 G/T aa719 however application of the two highest
stringency thresholds excluded this base call. Again, the germline
silent mutation in EGFR exon 20 aa787 was returned from the
analysis in all colorectal carcinoma samples in this study and has
been reported by others [12] (Table 1).
BRAF and KRAS analysis
Malignant melanoma (ID.1 and ID.2). BRAF: The stan-
dard-of-care mutation, exon 15 A/T aa600 [5] was detected in
both malignant melanoma clinical samples by the q-PCR method.
This finding was concordant with sequence data generated from
the IonTorrent NGS platform (ID.1 and ID.2) and GS Junior
(ID.2 only), Table 2. Unfortunately, the clinical sample, ID.1, was
exhausted and analysis with 454 GS Junior platform could not be
completed.
KRAS: Although not meeting the variant ‘passed’ criteria, it is
noteworthy that the clinically relevant KRAS mutation in exon 2
C/T aa12 was called (IonTorrent only) in ID.1, though at a low
frequency of 5.1%. This variant was not detected by q-PCR
sequencing of KRAS, Table 2.
Lung adenocarcinoma (ID.3-ID.10). BRAF: No mutations
in the BRAF gene were detected, concordant across all technol-
ogies.
KRAS: The important therapeutic KRAS mutation in colon
cancer was detected in ID.3 and ID.6 (exon 2 aa12), two EGFR
wildtype samples. Furthermore, the detection of KRAS muta-
tions by NGS was concordant with the gold standard methods,
Table 2. Within exon 2 of the KRAS gene, the GS Junior
AVA software (and CLC_AVA) but not IonTorrent, called
other variants with frequencies #7%, including a SNV at exon
2 aa14 with a COSMIC ID (http://www.sanger.ac.uk/perl/
genetics/CGP/cosmic?action=bygene&ln=KRAS&start=4&end=
20&coords=AA%3AAA) (Table 2). Interestingly, these multiple
variants were only present in ID.8 and ID.9 both of which harbour
several EGFR activating mutations (Table 1).
Colorectal carcinoma (ID.11-ID.13). All colorectal carci-
noma samples had been reported as BRAF and KRAS wildtype by
q-PCR sequencing. For KRAS analysis, this was concordant
across all technologies, however the BRAF mutation at codon 600
was called in 1/3 colorectal carcinoma samples though at a low
coverage equal to 4.38% and only by 1/4 analysis (IonTorrent,
Table 2).
T
a
b
le
1
.
C
o
n
t.
P
a
ti
e
n
t
E
G
F
R
q
-P
C
R
S
a
n
g
e
r
Io
n
T
o
rr
e
n
t
C
L
C
_
Io
n
T
o
rr
e
n
t
4
5
4
_
A
V
A
C
L
C
_
A
V
A
ID
L
o
ca
ti
o
n
E
x
o
n
A
A
S
N
V
/D
E
L
F
re
q
u
e
n
cy
C
o
v
e
ra
g
e
S
N
V
/D
E
L
F
re
q
u
e
n
cy
C
o
v
e
ra
g
e
S
N
V
/D
E
L
F
re
q
u
e
n
cy
C
o
v
e
ra
g
e
S
N
V
/D
E
L
F
re
q
u
e
n
cy
C
o
v
e
ra
g
e
C
R
C
1
2
5
5
2
4
1
7
0
7
EX
1
8
A
A
7
1
9
G
/T
8
.8
2
3
9
G
/T
7
.9
2
4
2
C
R
C
5
5
2
4
9
0
6
3
EX
2
0
A
A
7
8
7
G
/A
3
4
.4
2
7
0
G
/A
3
2
.4
3
1
8
1
3
LA
5
5
2
4
9
0
6
3
EX
2
0
A
A
7
8
7
G
/A
4
4
.1
6
8
G
/A
5
2
.5
9
7
2
G
/A
5
2
.5
9
4
7
T
h
e
EG
FR
e
xo
n
s
1
8
–
2
1
w
e
re
se
q
u
e
n
ce
d
an
d
co
m
p
ar
e
d
b
y
fo
u
r
m
e
th
o
d
s.
N
G
S
co
n
fi
rm
e
d
ac
ti
va
ti
n
g
m
u
ta
ti
o
n
s
in
EG
FR
co
n
co
rd
an
t
w
it
h
g
o
ld
st
an
d
ar
d
m
e
th
o
d
s,
as
w
e
ll
as
o
th
e
r
m
u
ta
ti
o
n
al
va
ri
an
ts
.C
LC
so
ft
w
ar
e
an
al
ys
is
w
as
p
e
rf
o
rm
e
d
to
co
n
fi
rm
o
r
d
e
n
y
b
as
e
ca
lls
.
D
e
l:d
e
le
ti
o
n
;
EX
:E
xo
n
;
L
A
:
lu
n
g
a
d
e
n
o
ca
rc
in
o
m
a
;
M
M
:
m
a
li
g
n
a
n
t
m
e
la
n
o
m
a
;
C
R
C
:
co
lo
re
ct
a
l
ca
n
ce
r.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
6
9
6
0
4
.t
0
0
1
Application of NGS for Clinical Cancer Diagnostics
PLOS ONE | www.plosone.org 4 July 2013 | Volume 8 | Issue 7 | e69604
T
a
b
le
2
.
B
R
A
F
an
d
K
R
A
S
m
u
ta
ti
o
n
al
an
al
ys
is
o
f
lu
n
g
ad
e
n
o
ca
rc
in
o
m
a,
m
al
ig
n
an
t
m
e
la
n
o
m
a
an
d
co
lo
re
ct
al
ca
rc
in
o
m
a
b
y
N
G
S
LA
:
lu
n
g
ad
e
n
o
ca
rc
in
o
m
a;
M
M
:
m
al
ig
n
an
t
m
e
la
n
o
m
a;
C
R
C
:
co
lo
re
ct
al
ca
n
ce
r.
P
a
ti
e
n
t
q
-P
C
R
Io
n
T
o
rr
e
n
t
C
L
C
_
Io
n
T
o
rr
e
n
t
4
5
4
_
A
V
A
C
L
C
_
A
V
A
ID
L
o
ca
ti
o
n
E
x
o
n
A
A
S
N
V
/D
E
L
F
re
q
u
e
n
cy
C
o
v
e
ra
g
e
S
N
V
/D
E
L
F
re
q
u
e
n
cy
C
o
v
e
ra
g
e
S
N
V
/D
E
L
F
re
q
u
e
n
cy
C
o
v
e
ra
g
e
S
N
V
/D
E
L
F
re
q
u
e
n
cy
C
o
v
e
ra
g
e
1
1
4
0
4
5
3
1
3
6
B
R
A
F
Ex
1
5
A
A
6
0
0
A
A
6
0
0
A
/T
1
9
.4
1
1
2
7
A
/T
1
9
1
0
9
8
-
-
M
M
2
5
3
9
8
2
8
4
K
R
A
S
Ex
2
A
A
1
2
C
/T
5
.1
9
3
9
4
2
M
M
1
4
0
4
5
3
1
3
6
B
R
A
F
Ex
1
5
A
A
6
0
0
A
A
6
0
0
A
/T
1
9
.5
9
3
4
A
/T
1
9
9
1
6
A
/T
9
.6
1
4
9
1
1
A
/T
9
.6
1
4
2
7
8
3
LA
2
5
3
9
8
2
8
4
K
R
A
S
Ex
2
A
A
1
2
A
A
1
2
C
/T
1
5
.8
1
5
5
0
C
/T
1
5
.7
1
5
5
1
C
/T
1
3
.6
7
5
4
4
C
/T
1
3
.5
6
2
0
9
4
LA
5
LA
6
LA
2
5
3
9
8
2
8
5
K
R
A
S
Ex
2
A
A
1
2
A
A
1
2
C
/A
4
9
.5
8
1
2
C
/A
4
9
.6
7
9
0
C
/A
6
0
.9
2
0
8
4
5
C
/A
3
9
.5
1
7
0
3
6
7
LA
8
2
5
3
9
8
2
3
4
K
R
A
S
Ex
2
A
A
6
C
/T
6
.4
7
0
4
7
C
/T
6
.2
6
5
4
9
LA
2
5
3
9
8
2
8
0
K
R
A
S
Ex
2
A
A
1
4
G
/A
5
.6
7
0
4
4
G
/A
5
.7
6
4
8
9
2
5
3
9
8
3
0
3
K
R
A
S
Ex
2
A
A
2
9
G
/A
6
.8
7
0
4
5
G
/A
5
.7
6
0
2
7
9
LA
2
5
3
9
8
2
7
9
K
R
A
S
Ex
2
A
A
1
4
C
/T
6
.6
1
0
0
5
4
C
/T
6
.2
9
2
5
3
1
0
LA
1
1
C
R
C
1
2
C
R
C
1
4
0
4
5
3
1
3
6
B
R
A
F
Ex
1
5
A
A
6
0
0
A
/T
4
.3
8
1
5
5
2
1
3
C
R
C
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
6
9
5
4
5
.t
0
0
2
Application of NGS for Clinical Cancer Diagnostics
PLOS ONE | www.plosone.org 5 July 2013 | Volume 8 | Issue 7 | e69604
Full analysis of IonTorrent AmpliSeq panel
Lung adenocarcinoma (ID.3-ID.10). As defined before,
variants ‘passed’ if present in 2/4 analyses: IonTorrent V2.0.1,
CLC_V2.0.1, IonTorrent V2.2 and CLC_V2.2, Figure 1. Several
SNVs and at different genomic positions, demonstrated by the
heat map ‘distribution of variants’, were observed in TP53 in
87.5% of lung adenocarcinomas (Figure 1, Table 3). Even at the
highest stringency threshold (QBVDiii = 500; Table 3), TP53
SNVs were called in 62.5% of samples. This is improbable, as
when we compare this frequency with the COSMIC database for
TP53 mutations in lung adenocarcinoma, the results are
discordant, Table 3. Five genes were flagged as mutant in all 8
lung adenocarcinoma samples namely RET, APC, FGFR3,
NPM1 and PDGFRA when the least stringent QBVD threshold
was applied (QBVDi= 71). By applying the highest threshold
(QBVDiii = 500), still 100% of samples had mutations in
PDGFRA and APC, while 37.5% and 75% of patient samples
had FGFR3 and RET mutations, respectively. For each of the five
genes, the findings are markedly discordant with COSMIC
frequencies (Table 3) and were regarded as false-positives.
Additionally, SNVs in NPM1 were disregarded as detection was
within a homopolymer region, a documented caveat of the
IonTorrent variant calling software [13]. Here, the NGS
methodology needs further software and chemistry improvements.
The importance of applying thresholds was addressed in relation
to other genes on the panel. A low stringency level (QBVDi= 71)
Figure 1. Distribution of variants detected using the Ion AmpliSeq Cancer Panel. A heat map was generated illustrating the variants
occurring in all 46 genes by both IonTorrent software versions in each of the clinical samples. COSMIC tracked variants are also described.
doi:10.1371/journal.pone.0069604.g001
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allowed the detection of STK11, DAPK2, CDKN2A, CDKN2B,
HIP1 and CSF1R SNVs in one or two (CDKN2B only) of the
patient samples. Again, these variants have not been considered in
the final gene profile for lung adenocarcinomas as they are
discordant with that reported by the COSMIC database (Figure 1,
Table 3). Other SNVs that were detected, even by a highly
stringent threshold approach, but excluded when referenced
against the COSMIC database included PIK3CA (62.5% of
samples vs 2.2% COSMIC frequency), KIT (37.5% vs 0.3%),
KDR (37.5% vs 4%), ABL1 (37.5% vs 0.8%), NOTCH (25% vs
1.5%), FGFR2 (62.5% vs 1.1%) and ATM (50% vs 5%).
Mutations that could be genuine but would require further
investigation in a larger patient cohort are AKT1, FGFR1 and
ERBB2, each occurring in 1/8 of the clinical samples and are
reported as low frequency occurring mutations in lung adenocar-
cinoma by the COSMIC database (Figure 1, Table 3).
Colorectal carcinoma (ID.11-ID.13). Analysis of ID.12 was
carried out using IonTorrent V2.01 and V2.2 as this sample was
sequenced prior to the software upgrade, hence included in the
heat map generated in Figure 1. ID.11 and ID.13 have been
analysed by V2.2 only, Table 4. Due to the limited numbers
available, we adjusted our inclusion criteria for the additional
genes interrogated by the Ion AmpliSeq panel. In each of the
colorectal carcinoma samples, SNVs were considered if a) detected
in 2/3 samples tested and b) called by both IonTorrent analysis
and CLC re-analysis. With this approach, FGFR3, PDGFRA,
APC, RET, ATM and TP53 were flagged; however, experience in
the larger lung adenocarcinoma cohort (Table 3) may call into
question the reliability of the former 4 genes, Table 4. The results
of ATM and TP53 do not allow analytical comment within this
small sample number.
Malignant melanoma (ID.1 and ID.2). As above, we
adjusted the inclusion criteria. SNVs were considered if detected
in both malignant melanoma (BRAF mutant) samples. Genes
included FGFR3, PDGFRA, APC, RET, NPM1 and PIK3CA. As
before, the reliability of the former 4 genes is questionable. NPM1
was disregarded as the mutation was flagged in a homopolymer
region. PIK3CA is a likely true mutation identified by the Ion
AmpliSeq panel (Figure 1) and requires future validation.
Threshold filtering
The gene information obtained from interrogation of the Ion
AmpliSeq panel was represented as a box plot (Figure S1)
demonstrating the importance of threshold application in SNV
detection in NGS. The lines represent each of the QBVD
thresholds (i = 71, ii = 259, iii = 500) and the proportion of gene
SNVs that are filtered according to what stringency level has been
applied.
Figure 2 demonstrates the relevance of ‘filtering by threshold
application’ of COSMIC SNVs in some of those patients with
standard-of-care mutations in EGFR (ID.9), KRAS (ID.3 and ID.6)
and BRAF (ID.1 and ID.2). For example, in ID.9 the lowest
threshold level of detection for large deletions, calls variants in 151
gene regions in the Ion AmpliSeq cancer panel, 14 of which have
been referenced in the COSMIC database. By applying an
internal SNV only detection capability in CLC, the number of
SNVs called in the full panel was reduced to 109 (14 COSMIC
references still remained). As expected, application of the QBVD
thresholds (i = 71, ii = 259 and iii = 500) resulted in a decrease in
the number of SNVs detected from 26 to 14 to 9 and those that
were COSMIC tracked, reduced from 6 to 4 to 1, respectively. An
interesting observation of this threshold approach is that clinically
important mutations in KRAS (ID.3 and ID.6) and BRAF (ID.1 and
ID.2) were still detected when a QBVDiii (500) was applied,
however, the clinically relevant mutation in EGFR would not have
been reported by applying this threshold, Figure 2.
Discussion
Generation of numerous DNA reads from significant portions of
the genome in little time will transform the way we interrogate
DNA in cancer diagnostics. The sooner NGS is fully fit for this
purpose, the easier it will be to interrogate numerous possible drug
targets per patient in a time-sensitive manner, and thus, design
broader short-term and long-term therapeutic strategies.
In our opinion, the current study has 4 main points of interest.
Firstly, NGS is reliable in detecting known standard-of-care
mutations with good sensitivity and specificity within our small
sample panel. For example, deletions in EGFR exon 19 and SNVs
in EGFR exon 18 aa719, exon 20 aa768 and exon 21 aa858 in
lung adenocarcinoma [8]; KRAS SNVs in exon 2 aa12 in 50% of
wildtype EGFR lung adenocarcinoma [14] and BRAF mutations at
exon 15 aa600 in DNA from malignant melanoma [15] were all
accurately identified by NGS, concordant with conventional
mutation detection methods.
Secondly, NGS called other mutations in EGFR, KRAS and
BRAF that represent standard-of-care but were undetected by
Sanger/q-PCR methods. This may be due to a) an increased
sensitivity of NGS or b) a lack of specificity of NGS. For example,
Table 3. NGS gene mutation detection using the Ion
AmpliSeq Cancer Panel in lung adenocarcinoma.
Gene QBVDi =500 QBVDii = 259 QBVDiii = 71 Cosmic %
PIK3CA 62.5 75 87.5 0.022
FGFR3 37.5 75 100 0
PDGFRA 100 100 100 4
KIT 37.5 37.5 37.5 0.003
KDR 37.5 37.5 37.5 4
APC 100 100 100 0.033
CSF1R 0 0 12.5 0.012
NPM1 50 75 100 0
HIP1 0 0 12.5 0
FGFR1 0 12.5 12.5 0.007
CDKN2A 0 0 12.5 0.122
CDKN2B 0 0 25 0.005
ABL1 37.5 37.5 37.5 0.008
NOTCH1 25 25 25 0.015
RET 75 100 100 0.014
FGFR2 62.5 62.5 62.5 0.011
ATM 50 50 50 5
AKT1 0 12.5 25 0.002
DAPK2 0 0 12.5 0
TP53 62.5 75 87.5 36
ERBB2 12.5 12.5 12.5 3
STK11 0 0 12.5 10
The proportion (%) of lung adenocarcinoma samples harbouring mutations in
the other genes interrogated by the panel and the resultant application of
different detection thresholds. Frequencies were compared with that observed
in the COSMIC database.
doi:10.1371/journal.pone.0069604.t003
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our preliminary dilution sensitivity tests for NGS, prior to the
validation of the technology, allowed us to indicate that the
standard-of-care mutation in EGFR exon 21 aa858 was detected at
1% in a mix of wildtype/mutant DNA from a cell line (data not
shown); however other mutations were also detectable at this level,
suggesting that the sensitivity assays are unlikely to reflect DNA
extracted from FFPE, thus making the direct correlation of NGS
sensitivity with that calculated for Sanger and q-PCR approaches,
10% and 5% respectively, questionable. In any case, it is likely that
many of these new mutations are not genuine and thus further
refinement of the technology is necessary.
Thirdly, the need for a better NGS technology is also a
consequence of the results obtained with the other 43 genes.
Again, it was out of the scope of this work to Sanger sequence
every mutation identified in the NGS analysis, and this is indeed
one of the limitations of our study. However, the approximation to
COSMIC tells us that for many of them, the current technology
may be over-calling mutations. This, which may be acceptable for
discovery studies where significant downstream validations need to
take place, is not appropriate in the context of routine cancer
diagnostics.
Fourthly, our study is a clear example of how the application of
new technologies to patient care will be dictated by bioinformatics
approaches as much as wet-bench related work. The importance
of the bioinformatics threshold approach in identifying credible
results is a clear illustration of this and calls for the presence of
molecular diagnostic bioinformaticians embedded in future reference
molecular diagnostic operations.
No doubt as NGS technologies (and bioinformatics tools)
evolve, accuracy will be enhanced thereby meeting our two
provisos: a) NGS technologies are as efficient as the current
detection methods in the diagnosis of those single genes that, for a
Table 4. NGS gene mutation detection using the Ion AmpliSeq Cancer Panel in colorectal carcinoma.
ID_11 ID_13
Ion Torrent 2.2 CLC_Ion Torrent Ion Torrent 2.2 CLC_Ion Torrent
Location Gene Location Gene Location Gene Location Gene
209113123 IDH1 178927969 PIK3CA
209113125 IDH1 178927972 PIK3CA
178927969 PIK3CA 178938877 PIK3CA
178927970 PIK3CA 1807894 FGFR3 1807894 FGFR3
178927972 PIK3CA 1808323 FGFR3
1807894 FGFR3 1807894 FGFR3 55141055 PDGFRA 55141055 PDGFRA
1807904 FGFR3 55593481 KIT 55593481 KIT
55141055 PDGFRA 55141055 PDGFRA 153247311 FBXW7 (DEL)
55152040 PDGFRA 153247316 FBXW7
55972974 KDR 55972974 KDR 112175770 APC 112175770 APC
153258992 FBXW7
112175193 APC 55249063 EGFR
112175770 APC 112175770 APC 116339643 MET
112175952 APC 38282213 FGFR1
55249063 EGFR 43613843 RET 43613843 RET
38282202 FGFR1 43609181 RET
38282213 FGFR1 89717599 PTEN
43613843 RET 43613843 RET 123274818 FGFR2
123274819 FGFR2 123274819 FGFR2
108155172 ATM 108123531 ATM
108155174 ATM 108155172 ATM
108218107 ATM 108155174 ATM
108236190 ATM 108173659 ATM
108236194 ATM 108218107 ATM
1207084 STK11 48923143 RB1 (DEL)
7578263 TP53 7578263 TP53
48604689 SMAD4 (DEL)
1207065 STK11
1207084 STK11
In conjunction with Figure 1 (ID.12), the genes in bold text occurred in 2/3 samples. ID.12 was sequenced prior to the software upgrade (V2.01, V2.2). ID.11 and ID.13 by
V2.2 only.
doi:10.1371/journal.pone.0069604.t004
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given cancer type, represent standard-of-care; and b) the extra
information that is generated in the process is of sufficient quality
to consider alternative therapies or be accepted for future research
endeavours. In future validations of NGS technology, one must
deal with the added benefits of the discovery of new mutations
versus the potential false positives that can result from altering the
threshold. The importance of applying thresholds has been
investigated here. In the situation where we observe lower
frequency (than the QBVDiii = 500), it is likely that the mutation
occurs in a small population of tumour cells or that the actual
sample contained many stromal cells for example, thereby diluting
the mutation frequency. The benefits of NGS are that the
technology is sensitive enough to detect mutations at low
frequency and in mixed tumour DNA samples; in such cases the
threshold must be lowered to detect this. We believe that the
sequencing of tumour samples for diagnostics must be carried on
in parallel with the sequencing of an adjacent histologically normal
sample; the latter acting as a baseline reference that should
eliminate false positives, reveal germline mutations in both samples
and finally reveal the true mutational profile of that tumour
sample. Investment into sequencing precision, accuracy, reliability
and bioinformatics will accelerate NGS integration into clinical
cancer diagnostics either as a parallel tool with conventional
sequencing methods or, in time, as a stand-alone approach to
mutation detection.
Supporting Information
Figure S1 The boxplot represents the distribution of
mutation variants, by coverage, obtained using the Ion
AmpliSeq Cancer Panel and analyzed by IonTorrent
V2.2 and CLC_V2.2. The lines represent QBVD thresholds (i,
ii, iii) demonstrating the number of variants filtered depending on
the level of detection applied.
(TIFF)
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